CAR-T: How far have we come and where are we going?

February 27, 2020

In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days. Parexel’s experts Mo Heidaran, Alexander Gee and host Alberto Grignolo, all part of our newly-integrated Regulatory & Access consulting unit, also weigh in on the current regulatory and reimbursement landscape for CAR-T and what we might look forward to in the future for this and other cell and gene therapies.

Previous Article
Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?
Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?

Next Article
Reflections on Cancer Drug Development Strategies with Newly-Introduced Chinese Regulations
Reflections on Cancer Drug Development Strategies with Newly-Introduced Chinese Regulations

The global cancer drug market is set to maintain strong growth over the next decade due to factors su...